Aspirin and COX-2 inhibitor use in patients with stage III colon cancer - Wikidata - wikimedia - TriplyDB

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

http://www.wikidata.org/entity/Q34736589

about

Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies Lipid metabolic reprogramming in cancer cells Eicosanoid pathway in colorectal cancer: Recent updates Combinatorial Control of mRNA Fates by RNA-Binding Proteins and Non-Coding RNAs Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer Chemopreventive Action by Ethanol-extracted Brazilian Green Propolis on Post-initiation Phase of Inflammation-associated Rat Colon Tumorigenesis.Low-dose aspirin and survival from lung cancer: a population-based cohort study Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer Vitamin D3 enhances the tumouricidal effects of 5-Fluorouracil through multipathway mechanisms in azoxymethane rat model of colon cancer Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer.Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer.Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2.Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding.Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.Surgical Options in the Treatment of Lower Gastrointestinal Tract Cancers.Interaction between Nonsteroidal Anti-inflammatory Drugs and Low-fat Dietary Intervention on Colorectal Cancer Incidence; the Women's Health Initiative (WHI) Dietary Modification Trial.Cancer Cell-Autonomous Parainflammation Mimics Immune Cell Infiltration.Cyclooxygenase-2 Induction by Amino Acid Deprivation Requires p38 Mitogen-Activated Protein Kinase in Human Glioma Cells.Aspirin and colorectal cancer: the promise of precision chemoprevention.Effect of statin and aspirin use on toxicity and pathological complete response rate of neo-adjuvant chemoradiation for rectal cancer.Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.Gut Microbiota, Inflammation, and Colorectal Cancer.Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases.Targeting cancer-related inflammation in the era of immunotherapy.Commonly used medications and endometrial cancer survival: a population-based cohort study.Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.Does antithrombotic therapy improve survival with colorectal cancer?Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice.RE: Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer.Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma.Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei.Linking Race, Cancer Outcomes, and Tissue Repair.Inflammation-associated microsatellite alterations: Mechanisms and significance in the prognosis of patients with colorectal cancer.Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin.Value of combined detection of serum carcino-embryonic antigen, carbohydrate antigen 19-9 and cyclooxygenase-2 in the diagnosis of colorectal cancer.

P2860

Q26749127-A9682256-2CDB-4862-A9EE-46AE192B9BC2 Q26751511-C9D7BC91-5785-4F1B-9B03-BBA926FD309D Q26774859-388EC7CE-947E-4718-A35D-4EE9BC56EAF8 Q26778011-9B53CF04-1CC5-4279-9D5B-DA660E23ECD7 Q26781248-7A90AD7A-F721-4D56-8A8D-6AF74558772A Q28084346-CFE6DABC-54DF-4E56-B6E5-224D2139B298 Q33622498-FF7A86ED-9964-46E1-A39B-417ADDB84208 Q35843033-5282A1BA-B6DA-4617-8A7F-BC719D4A8D70 Q35881186-8A8E8792-9722-42B5-A250-0C18401F934C Q35885755-554246A2-8CB9-4414-B010-80AA2295761C Q36023196-5CE8F397-EAC0-4C3B-9D9C-0551B90C339B Q36287410-3720BF01-FABC-485F-807F-F71B75D2589B Q36711029-AAC9D88E-57D2-48CD-A63C-2B6EF39543D0 Q36847557-77B8167E-B7FD-4664-823A-B297499482B7 Q37452750-12E7F88C-A754-41DE-A103-74DE15A5B44D Q37645070-9D1B6B2A-3EB4-43BF-8E44-A9403D442D1B Q37662128-E4197C2C-E1BD-4EC0-A0BF-DB898B98E6C7 Q38549935-34F086A5-CA30-44D9-95AF-57D601B55EDB Q38691375-1F92D4D3-C27F-49D5-B5CE-A8F11F47A098 Q38699338-60A356C3-BEBF-4458-A609-F3775F028426 Q38711044-447CBFA0-E721-4657-8B53-D90C01DFD19C Q38730064-96C389D2-3597-4A4D-806B-32B5D9551CC2 Q38762741-C1226FAB-C948-4919-882C-E8CE2CF76323 Q38855642-1F312A7D-8546-4CD6-B729-6E2BBA961167 Q38949434-537BDCC4-1817-4321-A728-B61EE589DB37 Q39037684-75165F9A-91C0-4D9E-AFFC-A5DFCC6225A3 Q39044981-B14A118C-A12D-4B7E-93D8-C1F585F029E4 Q40132826-85C279CD-1624-4528-B86A-C5B86D2F5100 Q40352933-31E8482F-80E1-498E-9BF1-078FE0B87890 Q40767715-FA201671-C2CA-44FD-BCF4-94A4C6F159C2 Q41521182-0B9EB0EB-F539-40DC-95F9-E982E296ECBD Q41565207-DF440FA7-4B9A-4BF8-8476-693B306864F4 Q43215154-E83665F1-7FC1-4BD7-BC1C-DF1B60299B29 Q45807888-54861E61-9EF9-4EA0-9DB8-8F8F1B6B7A86 Q47162953-B841CF1E-AA5D-4566-9C64-415F584A5DE1 Q47839645-8EEFB936-2884-4E6E-A176-1971B0ED021B Q49452061-2FCF5A08-03C3-49EF-A6C2-EACA06612F99 Q51411912-8FC0D7B4-6249-4072-AC4A-A97263B7984C Q55692174-7CF45198-4C2A-473C-B486-B483EF41E43E

P2860

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

http://www.wikidata.org/entity/Q34736589

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

@ast

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

@en

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

@nl

type

label

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

@ast

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

@en

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

@nl

prefLabel

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

@ast

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

@en

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

@nl

P1433

Q34736589-A33A4F1C-D880-4695-8C20-D6794A123A6A

P1476

Q34736589-C84077F3-A676-4A46-81AA-AC79734605E6

P2093

Q34736589-11C4BE28-45E0-43AF-A17A-D7D70D9F955C

Q34736589-54A27833-0962-4D67-9CFD-08035E76840D

Q34736589-6254C45C-4986-45ED-A5DD-E9EB4533E76E

Q34736589-6289D0A1-0879-4E57-B2D6-B3D32B21BE23

Q34736589-6A622B22-438A-4FF3-B208-C154FB1D7D2C

Q34736589-919874E7-6645-4E01-9396-F321D115F3A8

Q34736589-956AC1D1-E5A8-4F21-B725-021750357E32

Q34736589-A2415D02-F0C4-485B-8E32-8AAE7C2F7703

Q34736589-AB0E9C6F-94E0-43E2-8F9D-3BC1431F7DD4

Q34736589-CCA0FE95-73A3-4728-BD2A-79FED31D8DA2

P2860

Q34736589-01800717-27A7-419E-A497-8DEBD199D6A8

Q34736589-072DD1AE-A20C-4A85-83CC-05E43B53474F

Q34736589-0C4A7BBB-BF9C-4DA8-9882-992338FD4658

Q34736589-159DBD33-1A41-4472-ABEC-17D6FC80F6D9

Q34736589-1CB1F1F6-2AD6-4A13-B565-E8A99041715B

Q34736589-1EA1A077-E335-43D8-9299-1AD68E3B5D50

Q34736589-20E83C0B-6DE3-4CD8-BDF2-AA26CB23873F

Q34736589-2A33C712-131F-4E24-9973-8F3BEE0D0C4D

Q34736589-33D1B55A-29E0-4551-852E-3D492A9F6618

Q34736589-3908E3F7-72A6-4124-BB76-15B5B07F085A

P304

Q34736589-F2DA9A7E-8352-4E8C-9FBB-942D1A9BD61E

P31

Q34736589-C139988B-F2A1-48B6-847D-E725B3F537BF

P356

Q34736589-64C7B431-35DC-44A2-9905-974D537FBD70

P407

Q34736589-DC7DB313-C51B-4DEC-A900-5F4CA8F6FA66

P433

Q34736589-E53FE7C5-8DC7-4457-AD1B-B4FA569044A8

P478

Q34736589-5BE3052A-D761-4351-9423-0AE77178AA17

P50

Q34736589-29920A58-ACF7-476B-A91A-07B44D8304B9

Q34736589-7A5DEED4-E162-4AC8-BF82-327F3E577D2B

Q34736589-C678869B-DC24-4C55-9F78-21FB927983AC

Q34736589-EAA40985-4589-45C0-8097-698BB34077B9

Q34736589-FABF014F-F40E-49F0-BF24-D022C0F4DE19

P577

Q34736589-56CB2227-D44B-463B-817D-597EBB043DCF

P698

Q34736589-33FB2CC7-5280-4B98-B132-81AF2E47DF5A

P921

Q34736589-4BF0114F-F54C-4E96-AECA-A72272630DF4

P932

Q34736589-82F0A80C-24A6-4B57-B345-4E655BC4D706

P356

P1433

Journal of the National Cancer Institute

P1476

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

@en

P2093

Al B Benson

http://www.w3.org/2001/XMLSchema#string

Alan P Venook

http://www.w3.org/2001/XMLSchema#string

Alexander Hantel

http://www.w3.org/2001/XMLSchema#string

Andrew T Chan

http://www.w3.org/2001/XMLSchema#string

Donna Niedzwiecki

http://www.w3.org/2001/XMLSchema#string

Jennifer A Chan

http://www.w3.org/2001/XMLSchema#string

Kaori Sato

http://www.w3.org/2001/XMLSchema#string

Kimmie Ng

http://www.w3.org/2001/XMLSchema#string

Paul L Schaefer

http://www.w3.org/2001/XMLSchema#string

Renaud Whittom

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

Immunity, Inflammation, and Cancer

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

A randomized trial of aspirin to prevent colorectal adenomas

Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial

Celecoxib for the prevention of sporadic colorectal adenomas

Celecoxib for the prevention of colorectal adenomatous polyps

Long-term aspirin use and mortality in women

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

P304

345

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJU345

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Edward Giovannucci

Leonard B. Saltz

Charles S. Fuchs

Jeffrey A Meyerhardt

P577

2014-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25432409

http://www.w3.org/2001/XMLSchema#string

P921

P932

4271076

http://www.w3.org/2001/XMLSchema#string